CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. - Wikidata - awgldk - TriplyDB

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

http://www.wikidata.org/entity/Q35558644

about

Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells Tumor-specific Th17-polarized cells eradicate large established melanoma Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study Phorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line Using magnetic resonance imaging to evaluate dendritic cell-based vaccination Type I interferon is selectively required by dendritic cells for immune rejection of tumors Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.Natural immunity to pluripotency antigen OCT4 in humans.Tumour-infiltrating T-cell subpopulations in glioblastomas.MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Generation of more effective cancer vaccines Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response.Prostate-specific antigen vaccines for prostate cancer.The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells.HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritis Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.CD4 cells can be more efficient at tumor rejection than CD8 cells Antigenic targets for renal cell carcinoma immunotherapy.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis.Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.

P2860

Q24601213-48DB32BA-3F53-4590-A2B8-9A0D629116A0 Q24648032-F135D679-6B5A-4CC4-991E-392738BF94C6 Q24652592-17A2C8C7-8C99-40FD-977A-560704E34FB0 Q24792961-F301A951-C5E5-42C9-807A-1305ACE39570 Q27316977-B56E72D6-5CE7-4DB2-BF24-61099A77DAC7 Q28248500-F8815379-1D67-4B0B-8C09-770E5856368C Q28383234-94A37E9F-023E-4EA7-92CC-E4D4C4B98E30 Q30278537-EB6965F5-CA5B-43C8-8BCB-D2C36F22E12B Q30496580-81134803-E084-4B8D-96F4-BDF39DD3072A Q33584997-D8893708-7989-492C-9330-F7A7C8F57C16 Q33730129-F1DD0357-569D-4506-80A2-E87D16779EC9 Q33730171-7AD17BD1-1EBE-446F-A70E-779E4048843D Q33808144-21890AD4-76E1-4E95-A8CB-1F71B61573DC Q33928635-1F34666F-CF98-42B1-96F9-13E145925295 Q33943553-55415C6C-FE30-4543-8527-0DD99B52CC5A Q34034978-D8E3661A-7478-4955-B250-FC9397604706 Q34103645-94C67066-7533-4162-93D6-FEBF4C47E7F8 Q34169981-38D557BB-1D4F-4EC5-9D1D-1DAFE4D75651 Q34235915-5153D22D-EDF5-47FD-82D7-C9DEB464869A Q34243372-C2D49A91-7D6D-4E22-8F62-CA8C49F4CC0D Q34388367-7DEFAB55-889B-4692-A759-8A4D2173D877 Q34418112-85E43223-097A-46DC-9F8B-DD0901512EE8 Q34473746-6FA04533-0594-4CCB-A159-551CB26BD59E Q34602552-68364BAC-7D1A-4C8C-8D4E-77C403D70C74 Q34982772-605257BF-33F4-47D9-98F9-026DE6ED5DF7 Q34985471-A0E00137-AED2-4BDE-AAFF-82DAAA527552 Q35065407-B5BD5B88-DCC7-4ADC-9216-718B24A04319 Q35077753-FE07A0BB-3109-4825-BF36-56DA38B55559 Q35628806-0B53404E-48C1-4708-8562-24445DA0B711 Q35669339-9F2D1CFD-B5A0-479F-911F-88539EF6AB5F Q35828752-CF0E6CED-7344-4A2B-93B8-C9FFD552D70E Q35839925-AFC94364-0A03-4C69-B5AF-17510AAB9EF8 Q35925619-8E5B51D0-A0C5-4D8D-9B09-F1F689214D2F Q35990678-613CF51B-97F2-4C91-9EDF-6F9700A0EB62 Q36093442-D6965054-A132-41BD-BC3E-C2BC9D840E51 Q36184954-991374A3-1493-4A73-BD09-909DA8808EFD Q36349514-95A6A139-829A-4FC9-8F82-57F7CEADA492 Q36369462-1E825856-E53B-4079-A789-B03ADE997195 Q36369709-B1EBD05C-9DB9-407A-8C85-764952BEAB8E Q36370554-7E7A924B-05A9-4E52-B54D-69D5EC1A18EA

P2860

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

http://www.wikidata.org/entity/Q35558644

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@ast

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@en

type

label

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@ast

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@en

prefLabel

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@ast

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@en

P1433

Q35558644-59ECB1C0-2A28-47EB-9C2E-B95DB7A8BBC9

P1476

Q35558644-8131AEAD-C0B0-4A07-B977-47E3AA776131

P2093

Q35558644-0269C6CF-5236-456E-8016-762928BD6741

Q35558644-03CFE53A-F350-4163-976A-8249D1B40E6F

Q35558644-3C4DABE5-8D0D-468A-A7A1-41043B0BF364

Q35558644-52E31DE2-A7A9-44E8-8DEA-407526101BD7

Q35558644-64B6A3F6-1CCA-46FB-8DBA-57DDE777523A

Q35558644-81A666ED-6029-4A4A-91D1-55E33FEBBC16

Q35558644-8AF2496C-6C26-4E12-BE87-A5A3B468D6C9

P2860

Q35558644-01785A21-BD0F-484B-A241-195919E99C90

Q35558644-06C60850-EB02-4D6F-B37E-FB7EE4F062A8

Q35558644-0EC1F9D6-528C-4F3C-8354-F66B5843F37E

Q35558644-14EEE2EC-62E9-4887-BB42-099B5B5E0677

Q35558644-17607CF2-4FE1-4E01-A9CD-F471B65EFFB4

Q35558644-1777DCB8-36FE-454C-B10B-6F20DCF84544

Q35558644-1F817A37-E028-47C2-9958-D9A260CF5D26

Q35558644-208D981B-2DB5-4E53-84B4-2F63623D0648

Q35558644-2C212E3A-B344-4BD5-8D51-5E78ED57A1B4

Q35558644-383CEC67-6CDE-4ED5-B657-E256A78FBF35

P304

Q35558644-ACF9E674-361C-4DDA-AE83-B687A1010962

P31

Q35558644-D3E0439A-D614-4EB1-B38D-34E5CBF239BC

P356

Q35558644-C43E33C5-62B4-4444-A227-81C4F4258838

P407

Q35558644-4EE1F045-93C0-4921-85EF-BC97774EC969

P433

Q35558644-F1AAD252-C127-436C-84FA-5F1C3A686AEA

P478

Q35558644-688A6985-C481-4169-BF68-A9459F2AEAB6

P577

Q35558644-71A911B9-56ED-423A-AD38-62BA99D63E46

P5875

Q35558644-45BC565F-3390-4B57-A8E0-6AA92FC955C6

P698

Q35558644-1984B8E2-FDA0-43D0-85B4-8A5F3A21BE07

P932

Q35558644-3C416BEF-F2E7-4B81-B7F2-BF233E415865

P356

PNAS.96.15.8633

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.

@en

P2093

A Y Toledano

http://www.w3.org/2001/XMLSchema#string

D Mumberg

http://www.w3.org/2001/XMLSchema#string

H Schreiber

http://www.w3.org/2001/XMLSchema#string

M Philip

http://www.w3.org/2001/XMLSchema#string

P A Monach

http://www.w3.org/2001/XMLSchema#string

R D Schreiber

http://www.w3.org/2001/XMLSchema#string

S Wanderling

http://www.w3.org/2001/XMLSchema#string

P2860

Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins

A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines

A unique tumor antigen produced by a single amino acid substitution

Cellular responses to interferon-gamma

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.

Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.

Antiangiogenic gene therapy.

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

P304

8633-8638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.15.8633

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12887393

http://www.w3.org/2001/XMLSchema#string

P698

10411927

http://www.w3.org/2001/XMLSchema#string

P932

17568

http://www.w3.org/2001/XMLSchema#string